Portland Investment Counsel Inc. Acquires Shares of 250,000 Perspective Therapeutics, Inc. $CATX

Portland Investment Counsel Inc. bought a new stake in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 250,000 shares of the company’s stock, valued at approximately $852,000. Portland Investment Counsel Inc. owned 0.22% of Perspective Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in CATX. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the 4th quarter worth $28,000. Russell Investments Group Ltd. raised its stake in Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares during the period. nVerses Capital LLC bought a new stake in Perspective Therapeutics in the 4th quarter valued at about $31,000. AXQ Capital LP raised its stake in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after acquiring an additional 2,481 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in Perspective Therapeutics during the fourth quarter valued at about $35,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN CATX opened at $3.30 on Monday. Perspective Therapeutics, Inc. has a 52 week low of $1.96 and a 52 week high of $6.16. The business has a 50-day simple moving average of $3.11 and a two-hundred day simple moving average of $3.93.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%.The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.09 million. On average, equities research analysts expect that Perspective Therapeutics, Inc. will post -1.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CATX has been the subject of a number of research reports. Piper Sandler cut their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. BMO Capital Markets set a $11.00 price target on shares of Perspective Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Bank of America cut their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, August 14th. Finally, BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $11.50.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.